Clinical trial
Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
NCT03200691 is registered in ClinicalTrials.gov with Hangzhou Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Hangzhou Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 10, 2017
- Completion date
- July 1, 2020
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.